(Q37503243)

20 August 2017

1 reference

title

Challenges and progress in the development of a serogroup B meningococcal vaccine (English)

1 reference

20 August 2017

Manish Sadarangani

2

0 references

Andrew Pollard

series ordinal

4

object named as

Andrew J Pollard

1 reference

20 August 2017

Susan Lewis

1

1 reference

20 August 2017

J Claire Hoe

series ordinal

3

1 reference

20 August 2017

publication date

1 June 2009

1 reference

Expert Review of Vaccines

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

729-745

1 reference

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

20 August 2017

cites work

1 reference

Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis

21 January 2018

1 reference

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction

21 January 2018

1 reference

The future of meningococcal vaccines

21 January 2018

1 reference

Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

21 January 2018

1 reference

Immunologic response of man to group B meningococcal polysaccharide vaccines.

21 January 2018

1 reference

21 January 2018

1 reference

N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis

21 January 2018

1 reference

Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers.

21 January 2018

1 reference

Human immunity to the meningococcus. I. The role of humoral antibodies

21 January 2018

1 reference

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

21 January 2018

1 reference

Meningococcal surrogates of protection--serum bactericidal antibody activity

21 January 2018

1 reference

Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England

21 January 2018

1 reference

Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody

21 January 2018

1 reference

Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine

21 January 2018

1 reference

The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.

21 January 2018

1 reference

Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay

21 January 2018

1 reference

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

21 January 2018

1 reference

Outer membrane protein vesicle vaccines for meningococcal disease

21 January 2018

1 reference

Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage

21 January 2018

1 reference

Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870

21 January 2018

1 reference

Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines

21 January 2018

1 reference

Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.

21 January 2018

1 reference

Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil

21 January 2018

1 reference

Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.

21 January 2018

1 reference

Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland

21 January 2018

1 reference

A prospective study of the effectiveness of the New Zealand meningococcal B vaccine.

21 January 2018

1 reference

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

21 January 2018

1 reference

Glitazones in the treatment of cardiovascular risk factors

21 January 2018

1 reference

Carriage of Neisseria meningitidis and Neisseria lactamica in Infants and Children

21 January 2018

1 reference

The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica

21 January 2018

1 reference

Neisseria lactamica protects against experimental meningococcal infection

21 January 2018

1 reference

Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies.

21 January 2018

1 reference

Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac

21 January 2018

1 reference

Bacterial transferrin and lactoferrin receptors

21 January 2018

1 reference

Meningococcal Opa and Opc proteins: their role in colonization and invasion of human epithelial and endothelial cells.

21 January 2018

1 reference

Opacity-associated adhesin repertoire in hyperinvasive Neisseria meningitidis

21 January 2018

1 reference

Neisserial binding to CEACAM1 arrests the activation and proliferation of CD4+ T lymphocytes

21 January 2018

1 reference

Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function.

21 January 2018

1 reference

Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection

21 January 2018

1 reference

Lipo-oligosaccharide immunotyping of Neisseria meningitidis by a whole-cell ELISA with monoclonal antibodies

21 January 2018

1 reference

Naturally-occurring human serum antibodies to inner core lipopolysaccharide epitopes of Neisseria meningitidis protect against invasive meningococcal disease caused by isolates displaying homologous inner core structures

21 January 2018

1 reference

Functional opsonic activity of human serum antibodies to inner core lipopolysaccharide (galE) of serogroup B meningococci measured by flow cytometry

21 January 2018

1 reference

Reverse vaccinology, a genome-based approach to vaccine development

21 January 2018

1 reference

Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

21 January 2018

1 reference

NadA, a novel vaccine candidate of Neisseria meningitidis

21 January 2018

1 reference

Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci

21 January 2018

1 reference

Mucosal vaccination against serogroup B meningococci: induction of bactericidal antibodies and cellular immunity following intranasal immunization with NadA of Neisseria meningitidis and mutants of Escherichia coli heat-labile enterotoxin

21 January 2018

1 reference

Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA.

21 January 2018

1 reference

Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine

21 January 2018

1 reference

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

21 January 2018

1 reference

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

21 January 2018

1 reference

Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.

21 January 2018

1 reference

Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model

21 January 2018

1 reference

Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen

21 January 2018

1 reference

Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37.

21 January 2018

1 reference

A universal vaccine for serogroup B meningococcus

21 January 2018

1 reference

Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity

21 January 2018

1 reference

Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

21 January 2018

1 reference

Relative Immunogenicity of PorA Subtypes in a Multivalent Neisseria meningitidis Vaccine Is Not Dependent on Presentation Form

21 January 2018

1 reference

Immunogenicity and safety of three doses of a bivalent (B:4:p1.19,15 and B:4:p1.7-2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents

21 January 2018

1 reference

Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines

21 January 2018

1 reference

Additive and synergistic bactericidal activity of antibodies directed against minor outer membrane proteins of Neisseria meningitidis.

21 January 2018

1 reference

Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine

21 January 2018

1 reference

Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination

21 January 2018

1 reference

Lack of Association between Group B Meningococcal Disease and Autoimmune Disease

21 January 2018

1 reference

Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.09.30

1 reference

20 August 2017

1 reference